Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CagriSema Shows Superior Weight Loss in REDEFINE 2 Trial for Obesity & Diabetes
Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.
Product Name : CagriSema
Product Type : Peptide
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CagriSema Demonstrates Superior Weight Loss in Adults with Obesity in REDEFINE 1 Trial
Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.
Product Name : CagriSema
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk Successfully Completes Phase 2 Trial With Cagrisema in People With Type 2 Diabetes
Details : People treated with CagriSema (semaglutide) achieved a numerically higher body weight reduction of 15.6% compared to a reduction of 5.1% for people treated with semaglutide and 8.1% with cagrilintide alone.
Product Name : CagriSema
Product Type : Peptide
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable